{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:03:23Z","timestamp":1793239403679,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Previously reported post hoc multivariable analyses exploring predictors of confirmed virologic failure (CVF) with cabotegravir + rilpivirine long-acting (CAB + RPV LA) were expanded to include data beyond week 48, additional covariates, and additional participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pooled data from 1651 participants were used to explore dosing regimen (every 4 or every 8 weeks), demographic, viral, and pharmacokinetic covariates as potential predictors of CVF. Prior dosing regimen experience was accounted for using 2 populations. Two models were conducted in each population\u2014baseline factor analyses exploring factors known at baseline and multivariable analyses exploring baseline factors plus postbaseline model-predicted CAB\/RPV trough concentrations (4 and 44 weeks postinjection). Retained factors were evaluated to understand their contribution to CVF (alone or in combination).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 1.4% (n = 23\/1651) of participants had CVF through 152 weeks. The presence of RPV resistance-associated mutations, human immunodeficiency virus-1 subtype A6\/A1, and body mass index \u226530 kg\/m2 were associated with an increased risk of CVF (P &amp;lt; .05 adjusted incidence rate ratio), with participants with \u22652 of these baseline factors having a higher risk of CVF. Lower model-predicted CAB\/RPV troughs were additional factors retained for multivariable analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The presence of \u22652 baseline factors (RPV resistance-associated mutations, A6\/A1 subtype, and\/or body mass index \u226530 kg\/m2) was associated with increased CVF risk, consistent with prior analyses. Inclusion of initial model-predicted CAB\/RPV trough concentrations (\u2264first quartile) did not improve the prediction of CVF beyond the presence of a combination of \u22652 baseline factors, reinforcing the clinical utility of the baseline factors in the appropriate use of CAB + RPV LA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciad370","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T03:56:15Z","timestamp":1687319775000},"page":"1423-1431","source":"Crossref","is-referenced-by-count":127,"title":["Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6168-6745","authenticated-orcid":false,"given":"Chloe","family":"Orkin","sequence":"first","affiliation":[{"name":"SHARE Collaborative, Department of Immunobiology, Queen Mary University of London , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M","family":"Schapiro","sequence":"additional","affiliation":[{"name":"National Hemophilia Center, Sheba Medical Center , Ramat Gan , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo F","family":"Perno","sequence":"additional","affiliation":[{"name":"IRCCS Bambino Ges\u00f9 Pediatric Hospital , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R","family":"Kuritzkes","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Patel","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"DeMoor","sequence":"additional","affiliation":[{"name":"GSK , Collegeville, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dorey","sequence":"additional","affiliation":[{"name":"GSK , Mississauga , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwei","family":"Wang","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelong","family":"Han","sequence":"additional","affiliation":[{"name":"GSK , Collegeville, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Van Eygen","sequence":"additional","affiliation":[{"name":"Janssen Research & Development , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herta","family":"Crauwels","sequence":"additional","affiliation":[{"name":"Janssen Research & Development , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L","family":"Ford","sequence":"additional","affiliation":[{"name":"GSK , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L","family":"Latham","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marty","family":"St. Clair","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W","family":"Polli","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Vanveggel","sequence":"additional","affiliation":[{"name":"Janssen Research & Development , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kati","family":"Vandermeulen","sequence":"additional","affiliation":[{"name":"Janssen Research & Development , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmony P","family":"Garges","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Zolopa","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R","family":"Spreen","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"van Wyk","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Brentford , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy G","family":"Cutrell","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"2024021012510028300_ciad370-B1","author":"U.S. Department of Health and Human Services"},{"key":"2024021012510028300_ciad370-B2","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"2024021012510028300_ciad370-B3","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1016\/S2352-3018(21)00184-3","article-title":"Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"2024021012510028300_ciad370-B4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0000000000003025","article-title":"Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment","volume":"36","author":"Swindells","year":"2022","journal-title":"AIDS"},{"key":"2024021012510028300_ciad370-B5","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"2024021012510028300_ciad370-B6","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/S2352-3018(21)00185-5","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"8","author":"Jaeger","year":"2021","journal-title":"Lancet HIV"},{"key":"2024021012510028300_ciad370-B7","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"2024021012510028300_ciad370-B8","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"2024021012510028300_ciad370-B9","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"2024021012510028300_ciad370-B10","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 (HIV-1) infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study","volume":"76","author":"Overton","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024021012510028300_ciad370-B11","doi-asserted-by":"crossref","first-page":"e26006","DOI":"10.1002\/jia2.26006","article-title":"Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study","volume":"25","author":"Sinclair","year":"2022","journal-title":"J Int AIDS Soc"},{"issue":"Suppl 3","key":"2024021012510028300_ciad370-B12","first-page":"e25935","article-title":"Safety and effectiveness from the CARISEL study: phase 3b hybrid-III implementation study integrating cabotegravir + rilpivirine long-acting into European clinical settings","volume":"25","author":"Jonsson-Oldenb\u00fcttel","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"2024021012510028300_ciad370-B13","author":"van Welzen"},{"key":"2024021012510028300_ciad370-B14","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26003","article-title":"Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a hybrid III implementation-effectiveness study (CUSTOMIZE)","volume":"25","author":"Czarnogorski","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"2024021012510028300_ciad370-B15","author":"Borch"},{"key":"2024021012510028300_ciad370-B16","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/QAI.0000000000002466","article-title":"Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials","volume":"85","author":"Rizzardini","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024021012510028300_ciad370-B17","author":"Los Alamos National Laboratory"},{"key":"2024021012510028300_ciad370-B18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2174\/1570162X15666170815162052","article-title":"HIV type 1 integrase natural polymorphisms in viral variants circulating in FSU countries","volume":"15","author":"Lapovok","year":"2017","journal-title":"Curr HIV Res"},{"key":"2024021012510028300_ciad370-B19","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3390\/v12080838","article-title":"Genetic features of HIV-1 integrase sub-subtype A6 predominant in Russia and predicted susceptibility to INSTIs","volume":"12","author":"Kirichenko","year":"2020","journal-title":"Viruses"},{"key":"2024021012510028300_ciad370-B20","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study","volume":"207","author":"Eron","year":"2013","journal-title":"J Infect Dis"},{"key":"2024021012510028300_ciad370-B21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12977-018-0440-3","article-title":"Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir","volume":"15","author":"Oliveira","year":"2018","journal-title":"Retrovirology"},{"key":"2024021012510028300_ciad370-B22","author":"Boyce"},{"key":"2024021012510028300_ciad370-B23","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01702-21","article-title":"Impact of integrase sequences from HIV-1 subtypes A6\/A1 on the in vitro potency of cabotegravir or rilpivirine","volume":"66","author":"Jeffrey","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024021012510028300_ciad370-B24","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"key":"2024021012510028300_ciad370-B25","first-page":"111","article-title":"2019 update of the drug resistance mutations in HIV-1","volume":"27","author":"Wensing","year":"2019","journal-title":"Top Antivir Med"},{"key":"2024021012510028300_ciad370-B26","first-page":"132","article-title":"2015 update of the drug resistance mutations in HIV-1","volume":"23","author":"Wensing","year":"2015","journal-title":"Top Antivir Med"},{"key":"2024021012510028300_ciad370-B27","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"2024021012510028300_ciad370-B28","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1093\/jac\/dkab338","article-title":"Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV","volume":"76","author":"Neyens","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024021012510028300_ciad370-B29","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1111\/bcp.15439","article-title":"Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects","volume":"88","author":"Han","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 2","key":"2024021012510028300_ciad370-B30","doi-asserted-by":"crossref","first-page":"S865","DOI":"10.1093\/ofid\/ofz360.2173","article-title":"Pharmacokinetics of cabotegravir and rilpivirine long-acting injectables in HIV-infected individuals through 48 weeks in the FLAIR and ATLAS phase 3 studies","volume":"6","author":"Patel","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2024021012510028300_ciad370-B31","article-title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir + rilpivirine versus continuing bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): A randomised, open-label, phase 3b non-inferiority trial","volume":"2023","author":"Ramgopal","journal-title":"Lancet"},{"key":"2024021012510028300_ciad370-B32","author":"Elliot"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad370\/50950349\/ciad370.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/10\/1423\/56656681\/ciad370.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/10\/1423\/56656681\/ciad370.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T07:51:45Z","timestamp":1707551505000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/77\/10\/1423\/7204256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,6,21]]},"published-print":{"date-parts":[[2023,11,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad370","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,15]]},"published":{"date-parts":[[2023,6,21]]}}}